{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-26-000035","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2026-05-12T12:00:15+00:00","discovered_at":"2026-05-12T12:05:00.280224+00:00","generated_at":"2026-05-12T12:19:47.186526+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MacroGenics sells GMP manufacturing operations to Bora Pharma for $122.5M upfront","bullets":["Bora pays $122.5M cash at closing for MacroGenics' CDMO business, including Rockville site (11,000 L capacity) and Frederick warehouse.","Up to $5M in additional milestone payments to MacroGenics based on 2027-2028 CDMO manufacturing and professional development services.","Approximately 140 MacroGenics employees expected to be hired by Bora; transaction expected to close in Q3 2026.","MacroGenics will enter supply and transition services agreements to retain clinical manufacturing support for its pipeline.","Transaction approved by both boards; subject to customary closing conditions and consents."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-26-000035","json":"https://secwatch.observer/filing/0001125345-26-000035.json","markdown":"https://secwatch.observer/filing/0001125345-26-000035.md","text":"https://secwatch.observer/filing/0001125345-26-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000035/0001125345-26-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000035/mgnx-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T12:19:47.186526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d8d747e2edc12bce5c7f7cd609f28e01a808d12a","claim":"MACROGENICS INC entered into Asset Purchase Agreement with Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC valued at $122.5 million in cash (effective 2026-05-11).","evidence_excerpt":"On May 11, 2026, MacroGenics, Inc., a Delaware corporation (the \"Company\"), entered into an Asset Purchase Agreement (the \"Purchase Agreement\") with Bora Pharmaceuticals Co., Ltd., a company organized under the laws of Taiwan (\"Bora\"), and Bora Biologics USA, LLC, a Delaware limited liability company (collectively, the \"Purchaser\"), pursuant to which the Company agreed to sell to the Purchaser assets and current liabilities related to its GMP manufacturing operations, including its CDMO business (the \"CDMO Operations\") currently conducted by the Company at its manufacturing facility located at 9704 Medical Center Drive, Rockville, Maryland and related warehouse operations located at 4735 Arcadia Drive, Frederick, Maryland (excluding all research and related assets and operations of the Company) (the \"Transaction\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000035/0001125345-26-000035-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC"},{"label":"Value","value":"$122.5 million in cash"},{"label":"Effective","value":"2026-05-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}